Kolexia
Gutnecht Jean
Médecine interne
Chi De Frejus Saint Raphael
Fréjus, France
32 Activités
2 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Syndromes myélodysplasiques Lymphomes Leucémie à tricholeucocytes Maladie de Hodgkin Leucémie myéloïde Vascularite Monosomie

Industries

Janssen
4 collaboration(s)
Dernière en 2023
Novartis
3 collaboration(s)
Dernière en 2022
Sandoz
2 collaboration(s)
Dernière en 2022
Celgene
1 collaboration(s)
Dernière en 2020

Dernières activités

Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy.
Journal of the European Academy of Dermatology and Venereology : JEADV   22 juillet 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Blood cancer journal   27 mai 2020
French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up
Blood   13 novembre 2019
Large retrospective study of lenalidome-dexamethasone (Rd) in patients older than 80 with multiple myeloma (MM): Is less more?
2018 ASCO Annual Meeting I   01 juin 2018
Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Blood   01 janvier 2016
Erysipeloid Hodgkin lymphoma.
European journal of dermatology : EJD   12 novembre 2015
Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.
Experimental hematology & oncology   04 juillet 2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Leukemia & lymphoma   20 février 2015
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
Blood cancer journal   01 novembre 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
American journal of hematology   23 juillet 2013